Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dicyclomine
Drug ID BADD_D00659
Description Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.[L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967]
Indications and Usage including Colicky abdominal pain; diverticulitis
Marketing Status Prescription; Discontinued
ATC Code A03AA07
DrugBank ID DB00804
KEGG ID D07820
MeSH ID D004025
PubChem ID 3042
TTD Drug ID D07XJM
NDC Product Code Not Available
Synonyms Dicyclomine | Dicycloverin | Dicyclomine Hydrochloride | Hydrochloride, Dicyclomine | Merbentyl | Bentylol | Spascol | Di-Spaz | Di Spaz | Dibent | Diclomin | Lomine | OR-Tyl | OR Tyl | Bentyl | Di-Cyclonex | Di Cyclonex
Chemical Information
Molecular Formula C19H35NO2
CAS Registry Number 77-19-0
SMILES CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mood swings19.04.03.001--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.0010.000411%
Necrosis24.04.02.006; 08.03.03.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.0030.000411%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Pain08.01.08.0040.001027%
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Paralysis17.01.04.004--Not Available
Pruritus23.03.12.001--
Rash23.03.13.0010.000616%Not Available
Sensory loss17.02.07.007--Not Available
Shock24.06.02.002--Not Available
Sneezing22.02.05.011--
Somnolence17.02.04.006; 19.02.05.003--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.003--Not Available
Suppressed lactation21.05.02.003; 18.06.02.001--Not Available
Syncope17.02.04.008; 02.01.02.008; 24.06.02.012--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombosis24.01.01.0060.000411%Not Available
Transient global amnesia19.20.01.004; 17.03.02.004--Not Available
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages